MedTrace Logo

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

NCT02156739 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-22

No results posted yet for this study

Summary

This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate disodium and gadobutrol, may help doctors to see MRI images more clearly.

Conditions

  • Hepatocellular Carcinoma
  • Liver and Intrahepatic Bile Duct Disorder
  • Metastatic Malignant Neoplasm in the Liver
  • Primary Malignant Liver Neoplasm

Interventions

PROCEDURE

Contrast-enhanced Magnetic Resonance Imaging

Undergo contrast-enhanced MRI

DRUG

Gadobutrol

Given IV

DRUG

Gadoxetate Disodium

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Janio Szklaruk, MD, PHD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-13
Primary Completion
2026-06-01
Completion
2026-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02156739 on ClinicalTrials.gov